Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Either Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) or Advanced or Metastatic Soft Tissue Sarcomas (STS)

NCT00276302 is registered in ClinicalTrials.gov with Infinity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00276302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00276302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Either Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) or Advanced or Metastatic Soft Tissue Sarcomas (STS)
Lead sponsor
Infinity Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2005
Completion date
November 30, 2010
Enrollment
63 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumors, soft tissue sarcomas